PMID- 27486995
OWN - NLM
STAT- MEDLINE
DCOM- 20171113
LR  - 20220311
IS  - 1661-7819 (Electronic)
IS  - 1661-7800 (Linking)
VI  - 110
IP  - 4
DP  - 2016
TI  - Early Cord Metabolite Index and Outcome in Perinatal Asphyxia and 
      Hypoxic-Ischaemic Encephalopathy.
PG  - 296-302
AB  - BACKGROUND: A 1H-NMR-derived metabolomic index based on early umbilical cord 
      blood alterations of succinate, glycerol, 3-hydroxybutyrate and O-phosphocholine 
      has shown potential for the prediction of hypoxic-ischaemic encephalopathy (HIE) 
      severity. OBJECTIVE: To evaluate whether this metabolite score can predict 3-year 
      neurodevelopmental outcome in infants with perinatal asphyxia and HIE, compared 
      with current standard biochemical and clinical markers. METHODS: From September 
      2009 to June 2011, infants at risk of perinatal asphyxia were recruited from a 
      single maternity hospital. Cord blood was drawn and biobanked at delivery. 
      Neonates were monitored for development of encephalopathy both clinically and 
      electrographically. Neurodevelopmental outcome was assessed at 36-42 months using 
      the Bayley Scales of Infant and Toddler Development, ed. III (BSID-III). Death 
      and cerebral palsy were also considered as abnormal end points. RESULTS: 
      Thirty-one infants had both metabolomic analysis and neurodevelopmental outcome 
      at 36-42 months. No child had a severely abnormal BSID-III result. The metabolite 
      index significantly correlated with outcome (rho2 = 0.30, p < 0.01), which is 
      robust to predict both severe outcome (area under the receiver operating 
      characteristic curve: 0.92, p < 0.01) and intact survival (0.80, p = 0.01). There 
      was no correlation between the index score and performance in the individual 
      BSID-III subscales (cognitive, language, motor). CONCLUSIONS: The metabolite 
      index outperformed other standard biochemical markers at birth for prediction of 
      outcome at 3 years, but was not superior to EEG or the Sarnat score.
CI  - (c) 2016 S. Karger AG, Basel.
FAU - Ahearne, C E
AU  - Ahearne CE
AD  - The Irish Centre for Fetal and Neonatal Translational Research (INFANT), Cork, 
      Ireland.
FAU - Denihan, N M
AU  - Denihan NM
FAU - Walsh, B H
AU  - Walsh BH
FAU - Reinke, S N
AU  - Reinke SN
FAU - Kenny, L C
AU  - Kenny LC
FAU - Boylan, G B
AU  - Boylan GB
FAU - Broadhurst, D I
AU  - Broadhurst DI
FAU - Murray, D M
AU  - Murray DM
LA  - eng
SI  - ClinicalTrials.gov/NCT02019147
GR  - MFE-135481/CIHR/Canada
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20160803
PL  - Switzerland
TA  - Neonatology
JT  - Neonatology
JID - 101286577
RN  - 0 (Biomarkers)
SB  - IM
MH  - Asphyxia Neonatorum/*metabolism/*physiopathology
MH  - Australia
MH  - Biomarkers/metabolism
MH  - Cerebral Palsy/diagnosis
MH  - Child, Preschool
MH  - Electroencephalography
MH  - Female
MH  - Fetal Blood/*metabolism
MH  - Humans
MH  - Hypoxia-Ischemia, Brain/*metabolism/*physiopathology
MH  - Infant
MH  - Infant, Newborn
MH  - Language Development
MH  - Linear Models
MH  - Male
MH  - Metabolomics
MH  - ROC Curve
MH  - Severity of Illness Index
EDAT- 2016/11/05 06:00
MHDA- 2017/11/14 06:00
CRDT- 2016/08/04 06:00
PHST- 2016/01/14 00:00 [received]
PHST- 2016/04/28 00:00 [accepted]
PHST- 2016/11/05 06:00 [pubmed]
PHST- 2017/11/14 06:00 [medline]
PHST- 2016/08/04 06:00 [entrez]
AID - 000446556 [pii]
AID - 10.1159/000446556 [doi]
PST - ppublish
SO  - Neonatology. 2016;110(4):296-302. doi: 10.1159/000446556. Epub 2016 Aug 3.